The decision will add a third option for the third of adolescents in the U.S. who have not received at least one dose of the other two available shots.

A new form of the Roche cancer drug Tecentriq met its goals in a Phase 3 trial, the first in a series of studies the Swiss company and its peers could use to extend the patent lives of their lucrative immunotherapies.

Roche is expanding clinical testing of its experimental Alzheimer's disease drug gantenerumab, announcing Thursday the start of a late-stage trial in people with biological signs of the disease but no symptoms. The study will test whether treatment can slow cognitive decline over four years.

The Food and Drug Administration has approved AstraZeneca and Merck & Co.'s drug Lynparza for people with a genetic form of early breast cancer, a decision that could spur greater use of DNA testing in diagnosing and treating the disease.

Bacterial infections relating to medical implants place a huge burden on healthcare and cause great suffering to patients worldwide. Now, researchers at Chalmers University of Technology, Sweden

Eating a plant-centered diet during young adulthood is associated with a lower risk of heart disease in middle age, according to a long-term study with about 30 years of follow-up. A separate study with about 15 years of follow-up found that eating more plant-based foods that have been shown to lower cholesterol, called the 'Portfolio Diet', is associated with lower risk of cardiovascular disease in postmenopausal women.

More than 34 million people in the U.S. today have been diagnosed with diabetes, which is a chronic (long-lasting) health condition that affects how the body stores and uses sugars and other nutrients for energy. 

For years, Mexico has been fighting to preserve its native corn varieties from being eliminated by the chemical lobby and replaced with genetically modified (GMO) impostors. 

Department of Pharma has launched a PLI scheme for the promotion of domestic manufacturing by setting up greenfield plants in four different target segments with a total outlay of Rs 6,940 crore for the period 2020-21 to 2029-30.

The hype around antibody-drug conjugates (ADCs) has  been growing in recent years after big bucks deals and approvals from  the likes of AstraZeneca/Daiichi and Immunomedics putting a spotlight on  the approach.